Auris Medical to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Business Update on Thursday, March 14...
07 Março 2019 - 10:01AM
Zug, Switzerland, March 07, 2019 - Auris Medical
Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to
developing therapeutics that address important unmet medical needs
in neurotology and central nervous system disorders, today
announced that it will provide a business update and report its
financial results for the fourth quarter and full year 2018 on
Thursday, March 14, 2019. Following the announcement, Auris
Medical's management team will host a live conference call and
webcast at 8:00 am Eastern Time (2:00 pm Central European
Time).
To participate in this conference call, dial +1-866-966-1396
(toll free) or +1-631- 510-7495, and enter passcode 2489938.
A live webcast of the conference call can be accessed in the
Investor Relations section of the Auris Medical website at
www.aurismedical.com. A replay will be available approximately two
hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in neurotology and central nervous system
disorders. The company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125) and for the
treatment of antipsychotic-induced weight gain and somnolence
(AM-201). These projects have gone through two Phase 1 trials and
will move into proof-of-concept studies in 2019. In addition Auris
Medical has two Phase 3 programs under development: Sonsuvi®
(AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101)
for acute inner ear tinnitus. The Company was founded in 2003 and
is headquartered in Zug, Switzerland. The shares of Auris Medical
Holding AG trade on the NASDAQ Capital Market under the symbol
"EARS."
Investor contact: Joseph Green / Andrew
GibsonEdison Advisors for Auris Medical646-653-7030 /
7719jgreen@edisongroup.com / agibson@edisongroup.com
orinvestors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Auris Medical (NASDAQ:EARS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
Notícias em tempo-real sobre Auris Medical Holding AG da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de